Subsequent Events |
9 Months Ended |
---|---|
Sep. 30, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events |
12. Subsequent Events
On October 17, 2023 the Company’s board of directors approved, for a subset of employees of the Company, the issuance of 107,000 RSUs with an issuance cost of $5.72 and 61,550 SARs with an exercise price of $5.72 per share.
On October 30, 2023, SVB confirmed and extended the interest-only period on the $20 million term loan from January 1, 2024 to July 1, 2024 as the Company met both the revenue and net loss requirement outlined in the amendment to the SVB Loan Agreement.
On October 31, 2023, Augmedix Operating Corp., a wholly-owned subsidiary of the Company, entered into an amendment (the “Amendment”) to an office sublease with Turo, Inc., a Delaware corporation, for the property located at 111 Sutter Street, Suite 1300, San Francisco, California. The Amendment extends, among other things, the term of the original sublease until January 31, 2027, unless earlier terminated, and reduced the per square foot cost of the lease. |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|